Eisai’s Aricept Seen Driving 35 Percent Profit Increase For FY09
This article was originally published in PharmAsia News
Executive SummaryEisai expects a profit increase of about 35 percent in the fiscal year just beginning, with much of the increase due to its Aricept (donepezil) to treat Alzheimer's disease. Another major Eisai sales generator is expected to be its acquisition of U.S.-based MGI Pharma and its cancer drugs. Eisai can expect a large increase in expenses for research and development, however, because of the MGI purchase. In all, Eisai's net profit for the fiscal year that began April 1 is expected to increase by 35 percent. (Click here for more - a subscription may be required
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.